- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00520650
Health Evaluation of Abilify Long-term Therapy (HEALTH)
December 15, 2009 updated by: Taiwan Otsuka Pharm. Co., Ltd
This is a post-market surveillance, and the treatment to patients will be depended upon the decision based on physician's clinical judgment.
The health profiles during the switching period, after 12 weeks short-term use, and after 52 weeks long-term use of aripiprazole will be recorded and evaluated.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
Further study details as provided by Taiwan Otsuka Pharmaceutical Co., Ltd.
Study Type
Interventional
Enrollment (Actual)
245
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Changhua, Taiwan
- Changhua Christian Hospital
-
Hsinchu, Taiwan
- Cardinal Tien Hospital Hsin Chu Mercy Branch
-
Hualien, Taiwan
- Buddhist Tzu Chi General Hospital
-
Miaoli, Taiwan
- Wei Gong Memorial Hospital
-
Taichung, Taiwan
- Chung Shan Medical University Hospital
-
Tainan, Taiwan
- National Cheng Kung University Hospital
-
Taipei, Taiwan
- Tri-Service General Hospital
-
Taipei, Taiwan
- Cathay General Hospital
-
Yun-Lin, Taiwan
- National Taiwan University Hospital Yun-Lin Branch
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years to 63 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Male or female patients between the ages of 18 to 65.
- Having a DSM-IV diagnosis of schizophrenia or schizoaffective disorder.
- Who are currently taking antipsychotic drugs and clinically intolerable or inadequately controlled that is based upon the clinical judgment of the investigator.
Exclusion Criteria:
- Pregnant or breast feeding women or planning a pregnancy.
- Patient received electroconvulsive therapy within 4 weeks before the Screening Visit.
- A known allergy reaction to any antipsychotic medication (including but not limited to haloperidol, chlorpromazine, thioridazine, pimozide, risperidone, quetiapine, ziprasidone).
- Patient has clinically relevant organic, neurological, or cardiovascular diseases.
- Patient has a history of drug or alcohol abuse within the last 12 weeks.
- Acute psychosis, acute suicidal ideation, or any acute psychiatric condition that might require emergent intervention.
- Any clinical condition or significant concurrent disease judged by the investigator to complicate the evaluation of the study treatment.
- Having participated other investigational drug study and taken the investigation drug within one month prior to study entry.
- Depot neuroleptics should be discontinued at least 2 months prior to enrollment.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Change from baseline in Clinical Global Impression-Severity (CGI-S) scale after 52 weeks treatment.
Time Frame: Throughout the study
|
Throughout the study
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Change from baseline in CGI-S scale at each visit during the first 39 weeks treatment.
Time Frame: Throughout the study
|
Throughout the study
|
Change from baseline in total score on the Brief Psychiatric Rating Scale (BPRS) at each visit during the treatment period.
Time Frame: Throughout the study.
|
Throughout the study.
|
Change from baseline in total score on WHOQOL-BREF questionnaire at each visit during the treatment period.
Time Frame: Throughout the study.
|
Throughout the study.
|
Change from baseline in total score on PANSS (optional) questionnaire at each visit during the treatment period.
Time Frame: throughout the study
|
throughout the study
|
Change from baseline in total score on SFS (optional) questionnaire at 12 and 52 weeks treatment.
Time Frame: Throughout the study.
|
Throughout the study.
|
Change from Visit 2 on POM questionnaire at each visit during the 12-week switching period.
Time Frame: Throughout the study.
|
Throughout the study.
|
CGI-I scores after 12, 26, 39, and 52 weeks of treatment.
Time Frame: Throughout the study.
|
Throughout the study.
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Wei-Wen Lin, MD, Tri-Service General Hospital
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
August 1, 2006
Primary Completion (Actual)
April 1, 2009
Study Completion (Actual)
April 1, 2009
Study Registration Dates
First Submitted
August 23, 2007
First Submitted That Met QC Criteria
August 23, 2007
First Posted (Estimate)
August 24, 2007
Study Record Updates
Last Update Posted (Estimate)
December 16, 2009
Last Update Submitted That Met QC Criteria
December 15, 2009
Last Verified
December 1, 2009
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Mental Disorders
- Schizophrenia Spectrum and Other Psychotic Disorders
- Schizophrenia
- Psychotic Disorders
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Central Nervous System Depressants
- Antipsychotic Agents
- Tranquilizing Agents
- Psychotropic Drugs
- Serotonin Agents
- Antidepressive Agents
- Dopamine Agonists
- Dopamine Agents
- Serotonin 5-HT1 Receptor Agonists
- Serotonin Receptor Agonists
- Serotonin 5-HT2 Receptor Antagonists
- Serotonin Antagonists
- Dopamine D2 Receptor Antagonists
- Dopamine Antagonists
- Aripiprazole
Other Study ID Numbers
- 31-06-P01
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Schizophrenia
-
Organon and CoCompletedSchizophrenia, Paranoid | Schizophrenia, Disorganized | Schizophrenia, Undifferentiated
-
Organon and CoCompletedSchizophrenia, Paranoid | Schizophrenia, Disorganized | Schizophrenia, Undifferentiated
-
Bradley LegaRecruiting
-
All India Institute of Medical Sciences, BhubaneswarRecruitingTreatment Resistant SchizophreniaIndia
-
King's College LondonSouth London and Maudsley NHS Foundation TrustRecruitingTreatment-resistant Schizophrenia | Healthy Controls | Treatment-responsive SchizophreniaUnited Kingdom
-
University of Sao PauloUnknownRefractory Schizophrenia | Super Refractory SchizophreniaBrazil
-
Ohio State UniversityRecruitingTreatment-resistant SchizophreniaUnited States
-
University Hospital, BrestRecruitingSchizophrenia | Schizophrenia Prodromal | Schizophrenia, ChildhoodFrance
-
NYU Langone HealthNot yet recruitingTreatment-resistant SchizophreniaUnited States
-
Johns Hopkins UniversityNational Institute of Mental Health (NIMH)RecruitingTreatment-resistant SchizophreniaUnited States
Clinical Trials on Aripiprazole
-
National Institute on Alcohol Abuse and Alcoholism...Brown UniversityCompleted
-
Otsuka Beijing Research InstituteCompleted
-
H. Lundbeck A/SOtsuka Pharmaceutical Co., Ltd.CompletedSchizophreniaUnited States
-
University of California, Los AngelesAlkermes, Inc.TerminatedSchizophrenia | Schizophreniform Disorder | Schizoaffective Disorder, Depressive TypeUnited States
-
Otsuka Pharmaceutical Co., Ltd.CompletedMajor Depressive DisorderJapan
-
Veterans Medical Research FoundationBristol-Myers SquibbCompleted
-
Otsuka Pharmaceutical Co., Ltd.CompletedSchizophreniaJapan
-
Otsuka Pharmaceutical Development & Commercialization...CompletedSchizophreniaKorea, Republic of, United States, Estonia, Italy, Hungary, Bulgaria, Croatia, France, Poland, Thailand, Puerto Rico, Chile, South Africa, Austria, Belgium
-
Alkermes, Inc.CompletedSchizophreniaUnited States
-
Alkermes, Inc.CompletedSchizophreniaUnited States